World's Best Scientists 2026 revealed!
Silvia Novello

Silvia Novello

D-Index & Metrics

Medicine

D-Index
89
Citations
48622
World Ranking
12428
National Ranking
471

Silvia Novello publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Silvia Novello sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 727 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Silvia Novello D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Silvia Novello sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Silvia Novello is affiliated with the University of Turin in Italy and has a significant body of research in the field of pulmonary and respiratory medicine, oncology, and cancer research. Their work primarily focuses on lung cancer treatments, diagnosis, and immunotherapy.

The scientist's research touches on subjects including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Occupational and environmental lung diseases

In terms of their main and subfields of study, Novello has contributed to:

  • Medicine
  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Radiology, Nuclear Medicine and Imaging

Notable recent publications include:

  • Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023) - Journal of Clinical Oncology
  • Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer (2023) - New England Journal of Medicine
  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer (2020) - Journal of Clinical Oncology
  • Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial (2020) - Journal of Thoracic Oncology
  • Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC (2021) - Journal of Thoracic Oncology

Frequent coauthors include:

  • Paolo Bironzo
  • Francesco Passiglia
  • Luisella Righi
  • Giorgio V. Scagliotti
  • Maria Lucia Reale

Novello's publications often appear in a core set of journals frequently chosen for their work. Key publication venues include:

  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Lung Cancer
  • Critical Reviews in Oncology/Hematology
  • Journal of Clinical Oncology

Their contributions span multiple interrelated disciplines intersecting clinical, molecular, and immunological aspects of cancer research, with a consistent focus on advancing understanding and treatment modalities for lung cancer.

Best Publications

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

    Luis Paz-Ares;Alexander Luft;David Vicente;Ali Tafreshi

  • Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

    S Novello;F Barlesi;R Califano;R Califano;T Cufer

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial

    Cesare Gridelli;Francesco Perrone;Ciro Gallo;Silvio Cigolari

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

    S. Bovio;A. Cataldi;G. Reimondo;P. Sperone

  • Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

    Alice T Shaw;Tae Min Kim;Lucio Crinò;Cesare Gridelli

  • Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

    James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.

    Paolo Ceppi;Marco Volante;Silvia Saviozzi;Ida Rapa

  • Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

    Giorgio Scagliotti;Silvia Novello;Joachim von Pawel;Martin Reck

  • ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

    P. Ceppi;M. Volante;S. Novello;I. Rapa

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

    Paolo Maione;Francesco Perrone;Ciro Gallo;Luigi Manzione

  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

    Mark A. Socinski;Silvia Novello;Julie R. Brahmer;Rafael Rosell

  • Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

    G. Selvaggi;S. Novello;V. Torri;E. Leonardo

Frequent Co-Authors

Giorgio V. Scagliotti
Giorgio V. Scagliotti University of Turin
Mauro Papotti
Mauro Papotti University of Turin
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Julien Mazieres
Julien Mazieres Paul Sabatier University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Rafael Rosell
Rafael Rosell Autonomous University of Barcelona
David Planchard
David Planchard Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is a diverse field, and there are several related online degrees that offer flexible options for those interested in healthcare careers. For example, pursuing a nutritionist online degree can open doors to careers in dietary consulting, public health, and wellness programs without needing to attend in-person classes.

For those interested in healthcare leadership and administration, accredited programs can be pursued remotely. The top cahme accredited mha programs deliver rigorous education online while meeting essential industry standards.

If you are already a registered nurse and want to advance your qualifications, online rn to bsn programs no clinicals are available. These programs cater to working professionals by offering maximum flexibility and no mandatory clinical rotations.

Nurses aiming for the highest practice roles can consider dnp online programs. These doctoral programs prepare nurses for leadership, advanced practice, and academic positions—all with the convenience of online study.

Each pathway provides unique opportunities for advancing your medical or healthcare career on your own terms.

Best Scientists Citing Silvia Novello

Trending Scientists

Recently Published Articles